Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't know which analyst, will try to find out, but how many .0001s are covered by any Wall Street Journal analyst? The Forbes article doesn't mention RNVA, but how many listed companies have a CAH as their core business? Only a fraction of other listed health care companies' revenues are CAH driven.
Wake up call!!! An analyst the Wall Street Journal follows just began covering RNVA this month! Initiated as a hold. Proof: https://www.wsj.com/market-data/quotes/RNVA/research-ratings
And remember this Forbes article last month? https://www.forbes.com/sites/gebai/2024/01/21/rural-urban-healthcare-access-gap-its-all-about-the-fixed-costs/?sh=75d03b146288
Who doesn't know what time it is?
My first 000 breakout netted me $35k on $1000. I spotted some value the market was overlooking. With RNVA, the value is not so easy to overlook. It's all in the SEC filings and updates.
In my 30 years of OTC trading, I have never been more certain a stock will break out of the 000s. It's already worth more than that by any valuation measure.
Good point.. My numbers don't include the interest savings but there would have been some interest savings accumulated from the $2.9 million debt reduction plus maybe a month or two of interest savings on the note restructured in late October.
Let's say the cost of revenues didn't improve in Q4, though we know it would have under the CAH reimusement system, we still know that RNVA turned over $20 million in 2023 revenue with a profit of at least $2 million, bare minimum. That's a P/E of 2 on a 40 billion share OS. Enough with all the bedwetting over share structure. People just need to buy the damned stock. It's underpriced to the point of being downright ridiculously cheap.
"2023 saw inpatient admissions increase by over 75% compared to 2022" (Jan 16 update) Along with other service increases, that translates to Q4 revenues of $5.5-7.5 million. Cost-based CAH reimbursements give us some certainty that the cost of revenues was about 40-45%. Other expenses being roughly equal or maybe increasing slightly, Q4 earnings were $1-2.5 million.
No kidding. We're looking at what, $2-3 million in 2023 earnings on $20-23 million in revenues. That's a fairly minimal projection based on all the filings and updates. Sometimes I wonder if anyone reads earnings reports anymore.
With a current P/E under 2, the share structure must not 'suck" that much.
Last trading day of the week before a Monday holiday. Tuesday opening might get really interesting.
Your lack of information is not my problem. Learn how to read earnings reports.
18 months of dynamic revenue and earnings growth with $1 million per quarter in debt reduction in 2023. They didn't read earnings reports then. They don't read them now. Probably wouldn't understand them if they did.
Interesting how that question comes from the one who is doing one post after another..., excessively or obsessively, we never know which.
Thanks for the update.
Last six 10Qs clearly show a company turnaround with new Myrtle Recovery revenues still to come. I gave up trying to fact check GeekOfSkidRow and his fellow losers. Everybody just needs to do their own DD and let the facts speak for themselves..
Current, SEC compliant quarterly reports. That's proof here on this planet.
The update last month showed the OS had not changed since early Q4, yet the nonsequential trades through the transfer agent have continued. You must hold or recieve the actual stock certificates to trade directly through the transfer agent. Therefore, buybacks are a likely explanation, if not a new commercial investor accumulating common shares. Somebody is on the buy side of those trades. We know that much.
You never know when.
Markets were selling yesterday. Traders will do what they decide to do whenever they decide to do it. The street can trade up RNVA whenever it wants.
I think the clamp down on insider manipulation is a good thing. Sure, it dampened OTC activity, but it invites investors to reward value instead of rumors and momentum that insiders can't cash in on anymore.
Bad luck for casino traders. New day for value investors. RNVA.
Buzz going around about a RNVA run this week. If so, it's just the beginning of the beginning.
A whole 100 million. OMG the sky is falling.
So, let me get this straight. You lost your money when RNVA was losing money because you didn't understand dilution paid for the losses. Now you think $2 million in earnings causes $2 million in dilution. Okie dokie.
Nope, .0001 restistance thinned out already. Just needs some moderate volume on the bid side.
Like ringing a gong.
It appears the same 400 million sell order has been entered and pulled few times in recent trading days. Somebody posted here that it was his 400 million but suggested he really didn't intend to sell. I would suggest it's uncertainty, thinking he should sell when he sees little buying interest then changing his mind when he sees some volume buying. There's always some of that. We're close to taking on an .0002 ask.
Tastes like chicken.
Not diddly. More than that traded already today.
That'll take out .0002s, maybe some .0003s IMO.
Nope, not anything close to that. Ask about to go. It's gettiing obvious now.
Down from 200 and 400 million increments.
Might be all they have.
It's in the prospectus as amended. Doesn't have to sell but can hold untill QX or Nasdaq uplisting, but they can sell at .00014 any time before.
Holding long IMO. Nothing to lose. They have a standing, binding buyout offer in hand.
We really haven't had much volume for two or three months.
Hmmm, people who believe ridiculous posts like yours maybe.
Looks like someone answered your question with cash.
2023 revenue over $20 million at a "run rate of $25-30 million" py and climbing with earnings of $2-3 miilion. Debt reduction rate through Q3 of $1 million per quarter. $1.5 million py in interest savings from debt restructuring so far on top of the interest savings from debt reduction. News comining anytime on more "restructuring of debt and other securities."
Price targets set at a forward P/E of 20-25 get it there. The OS doesn't matter. It's about the EPS and P/E now.